四川宏明博思藥業(yè)有限公司成立于2013年，專注于原料藥和制劑的生產(chǎn)?，F(xiàn)有員工400余人，主要生產(chǎn)高端劑型如注射劑、凍干粉針劑、片劑和膠囊劑。宏明博思的凍干粉針制劑生產(chǎn)線已獲得EU GMP，并通過巴西ANVISA現(xiàn)場(chǎng)檢查。目前四川宏明博思凍干粉針制劑的多個(gè)產(chǎn)品在巴西、智利、秘魯、危地馬拉、泰國(guó)、菲律賓、馬來西亞、南非、澳大利亞等開展注冊(cè)中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
